GB2064336A - Device for dispensing medicaments - Google Patents

Device for dispensing medicaments Download PDF

Info

Publication number
GB2064336A
GB2064336A GB8039174A GB8039174A GB2064336A GB 2064336 A GB2064336 A GB 2064336A GB 8039174 A GB8039174 A GB 8039174A GB 8039174 A GB8039174 A GB 8039174A GB 2064336 A GB2064336 A GB 2064336A
Authority
GB
United Kingdom
Prior art keywords
capsule
sleeve
chamber
body shell
retaining means
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8039174A
Other versions
GB2064336B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB8039174A priority Critical patent/GB2064336B/en
Priority to CY130880A priority patent/CY1308A/en
Publication of GB2064336A publication Critical patent/GB2064336A/en
Application granted granted Critical
Publication of GB2064336B publication Critical patent/GB2064336B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

A device by which powdered medicaments can be orally or nasally administered to a patient comprises a body shell (1) defining a portion of a chamber (2). A nozzle or mouthpiece (3) is located at the forward end of the body shell. The body shell is open at the rear end. A sleeve (7) is fitted on the outside of the rear end portion of the body shell (1) and is rotatable and axially movable with respect to it. The sleeve has a rear wall (8) which closes the open rear end of the chamber (2). A capsule retaining means (11) extends through the rear wall (8) of the sleeve into the chamber. The capsule retaining means has an external entry opening for a capsule at the rear of the sleeve. An abutment (13) is fixed inside the chamber (2) in such a position with respect to the retaining means (11) that a capsule retained in the retaining means and projecting from it into the chamber will engage the abutment when the sleeve is rotated with respect to the body shell. This separates the projecting portion of the capsule from the remainder of the capsule. A grid or guard (4) prevents the separated portion of the capsule from passing through the nozzle or mouthpiece (3). An air inlet opening (14) extends through the rear wall of the sleeve into the chamber (2). <IMAGE>

Description

SPECIFICATION Device for dispensing medicaments This invention relates to inhalation devices by which powdered medicaments can be orally or nasally administered to a patient.
It is well known to administer powdered medicamentsto the lung bronchioles of a patient by means of inhalation devices having mouthpieces which enable the medicamentto be inhaledthroughthe mouth of the patient. The "mouthpiece" may if desired, be modified so that it is possible to inhale through a nostril of the patient. The medicament in such cases is supplied in gelatine capsules which are inserted in the device and opened in some suitable way after which inhalation through the mouthpiece will cause the powdered medicamentto be released from the capsule and pass into the patient.
Capsules containing such medicaments are generally of gelatine and of elongated "torpedo" shape and are constructed in two parts, one of which (called the capsule body) is partly enclosed within the other (called the capsule cap). The contacting portions of the two capsule parts are often provided with grooves and/or ribs which have the effect of "locking" the two capsule parts together. The inhalation devices for use with such capsules normally have a chamber arranged to receive a capsule containing the medicament. An air inlet aperture, or a plurality of such apertures, lead into the chamber in a generally transversal direction and air from the chamber can be inhaled through a nozzle.The air inlet aperture or apertures is/are so arranged that the air flow caused by inhalation through the nozzle will cause the contents of an opened capsule within the chamber to be released and withdrawn through the nozzle.
According to the present invention, there is provided a device comprising a body shell defining a portion of a chamber which has a nozzle at a forward end and which is open at the rear end, a sleeve fitted on the outside of the body shell and rotatable with respect to it and having a rear wall closing the open rear end of the chamber, a capsule retaining means extending through the said rear wall of the sleeve into the chamber and having an external entry opening for a capsule at the rear of the sleeve, an abutment fixed inside the chamber in such a position with respect to the capsule retaining means that a capsule retained in the retaining means and projecting from it into the chamber will engage the abutment when the sleeve is rotated with respect to the body shell thereby to separate the projecting portion of the capsule from the remainder of the capsule, a guard for preventing the separated portion of the capsule from passing through the nozzle and an air inlet opening extending through the said rear wall of the sleeve into the chamber. A stop may be provided to limit the rotation of the sleeve with respect to the body shell.
An embodiment of the invention is illustrated in the accompanying schematic drawings in which: Figure 1 is a sectional elevation of a device according to the invention, Figure 2 is an exploded elevation, Figure 3 is a rear view of the device, Figure 4 is a section on the line A-A of Figure 2, and Figure 5 is a view similar to Fig 1 illustrating a modification.
In the illustrated embodiment of the invention, an inhalation device is conveniently, but not essentially of a plastics material. The device comprises a cylindrical body shell 1, the interior of which defines a portion of a cylindrical capsule-receiving chamber 2.
Secured to one end of the body shell, herein considered to be the forward end, is a nozzle or mouthpiece 3. A perforated guard 4, which defines the front end of the chamber2, is fixed inside the body shell 1 and prevents portions of a capsule inside the chamber 2 being withdrawn through the mouthpiece 3 when a patient inhales. An abutment 5 serving as a stop for a purpose hereinafterto be described, is located on the outside of the body shell 1. This stop or abutment 5 projects to the rear of a shoulder 6 extending around the body shell 1 at the rear of the mouthpiece 3. The rear end of the body shell 1 is open.
A cylindrical sleeve 7 is fitted on the rear end portion of the body shell 1. The sleeve is both rotatable and axially slidable on the body shell 1. The sleeve has a rear end wall 8 which closes the open rear end of the body shell 1 and thus of the chamber 2. The sleeve 7 has a recessed forward end, the recess being formed by a part cylindrical extension of the sleeve. The sleeve 7 may be slid off the rear end portion of the body shell 1 to provide access to the interior of the chamber 2, but when the device is in use by a patient, the forward or recessed end of the sleeve abuts againstthe shoulder 6 atthe rear end of the mouthpiece thereby to define a slot 9 in which the stop 5 is located.The ends of the recess in the forward end of the sleeve form abutments 10 against which the stop 5 can engage when the sleeve 7 is rotated in one direction or other with respect to the body shell so that rotation of the sleeve 7 is limited.
A capsule retaining means 11 in the form of a tube is arranged at, and extends through, the rear end wall 8 of the sleeve 7. A forward end portion of the retaining means 11 extends into the rear end of the sleeve 7, i.e. into the chamber 2, as clearly shown in Figure 1 of the drawings. The retaining means 11 has a passage 12 which opens at the forward end into the chamber 2 and atthe rear end opens externally of the rear wall 8 of the sleeve. A capsule may be entered through the open rear end of this passage and retained in the passage.The retaining means 11 is of such a length that when the sleeve 7 is in its fully forward position on the body shell 1 and a capsule is pushed, preferably body first, into the passage 12, the capsule cap (CC) will be retained in the retaining means and the capsule body (CB) will protrude into the chamber as illustrated in Figure 1. The retaining means 11 may be a separate member fitted into the rear wall 8 of the sleeve 7 or it may be, as illustrated, an integral part of the sleeve 7, i.e. the tube 11 and the sleeve 7 may be a single moulding.
As shown in Figure 3, the passage 12 in the retaining means 11 is substantially square in cross-section.
The size and shape of the passage 12 is such that the retaining means 12 will squeeze and deform at least part of the overlapping portions of the capsule body (CB) and the capsule cap (CC), thereby to break or weaken the lock between the two capsule parts.
An abutment in the form of a fin or rib 13 is fixed to the inside of the body shell 1. The abutment 13 and the retaining means 11 are so disposed with respect to each other that when the body (CB) of a capsule which has been inserted into the passage 12 of the retaining means projects from the retaining means into the chamber 2, the projecting body (CB) of the capsule will engage a side of the fin or rib 13 when the sleeve 7 is rotated with respect to the body shell thereby to separate the two capsule parts. The forward separated capsule portion will, of course, fall into the chamber 2 and the remainder of the capsule will of course be retained in the passage 12 of the capsule retaining means.
Below the retaining means 11, is an air inlet formed by two arcuate slots 14 extending through the rear wall 8 of the sleeve and opening into the chamber 2. Alternatively, the slots 14 may be replaced by a single linear or arcuate slot or by a row of holes or by a single round hole or a group of holes not arranged in rows. When air is aspirated by a patient through the nozzle or mouthpiece 3, the capsule portion (CB) separated from the remainder of the capsule and disposed in the chamber 2 will be agitated. This agitation serves to empty powder from the separated capsule body (CB). The abutment 13 will assist in this because it acts as a "kick-bar" in that the capsule body repeatedly collides with the rib.The agitation and vibration produced by such collision assists in the operation of emptying medi camentfrom the portion of the capsule in the chamber 2. Medicament in the portion of the capsule remaining in the retaining means will of course be withdrawn as the patient aspirates through the mouthpiece or nozzle 3.
If desired, the fin or rib 13 may be shorter than as illustrated in Figure 1, and only of sufficient length to engage the projecting portion (CB of the capsule held in the retaining means 11 and a separate "kickbar" or a plurality of such kick-bars may then, if desired, be provided.
In the modification illustrated in Figure 5, the retaining means 11 opens into a compartment 15 which is a rearward extension of the sleeve 7 and which is closed by a removable cover 16. The compartment may have a suitable air inlet andlor the cover may be removed when the device is in use.
The cover has pusher means in the form of an inwardly projecting ring 17 of sufficient depth to engage the cap (CC) of a capsule engaged in the entry opening of the retaining means 11 and press it forward when the cover is fitted in its closed position. To make this possible, the wall of the retaining means has lead-in portion with a suitable groove so that the ring 17 can enter the opening. When a new capsule is inserted in the retaining means, the entering capsule body (CB) will push the capsule cap (CC) of the previously used capsule or of the retaining means and into the chamber.
In a further modification, the pusher means is not a ring but is a peg or the like engageable with a capsule in the retaining means.

Claims (6)

1. An inhalation device by which powdered medicaments can be orally or nasally administered to a patient comprising a body shell defining a portion of a chamber which has a nozzle at a forward end and which is open atthe rear end, a sleeve fitted on the outside of the body shell and rotatable with respect to it and having a rearwall closing the open rear end of the chamber, a capsule retaining means extending through the said rear wall of the sleeve into the chamber and having an external entry opening for a capsule at the rear of the sleeve, an abutment fixed inside the chamber in such a position with respect to the capsule retaining meansthatthe capsule retained in the retaining means and projecting from it into the chamber will engage the abutment when the sleeve is rotated with respect to the body shell thereby to separate the projecting portion of the capsule from the remainder of the capsule, a guard for preventing the separated portion of the capsule from passing through the nozzle, and an air inlet opening extending through the said rearwall of the sleeve into the chamber.
2. A device as claimed in claim 1, which has a stop to limit rotation of the sleeve with respect to the body shell.
3. A device as claimed in claim 1, wherein the body shell has a rearwardly directed shoulder from which a stop extends rearwardly and the sleeve has a recessed forward end engaged with the shoulder to define a slot in which the stop is located, the stop being engaged with opposite ends of the slot when the sleeve and body shell are rotated with respect to one another thereby to limit relative rotation between the sleeve and the body shell.
4. A device as claimed in any of the preceding claims wherein the sleeve has at the rear an extension compartment into which the entry opening of the retaining means opens, the extension compartment having a removable cover provided with pusher means which, when the cover is fitted to the extension compartment, engages the end of a capsule retained in the retaining means, pushes the capsule in forwards.
5. A device as claimed in claim 3, wherein the pusher means is an annular ring inside the cover.
6. An inhalation device by which powdered medicament can be orally or nasally administered to a patient substantially as herein described with reference to the accompanying drawings.
GB8039174A 1979-12-06 1980-12-05 Device for dispensing medicaments Expired GB2064336B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB8039174A GB2064336B (en) 1979-12-06 1980-12-05 Device for dispensing medicaments
CY130880A CY1308A (en) 1979-12-06 1980-12-05 Device for dispensing medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7942208 1979-12-06
GB8039174A GB2064336B (en) 1979-12-06 1980-12-05 Device for dispensing medicaments

Publications (2)

Publication Number Publication Date
GB2064336A true GB2064336A (en) 1981-06-17
GB2064336B GB2064336B (en) 1984-03-14

Family

ID=26273811

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8039174A Expired GB2064336B (en) 1979-12-06 1980-12-05 Device for dispensing medicaments

Country Status (2)

Country Link
CY (1) CY1308A (en)
GB (1) GB2064336B (en)

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271029A2 (en) * 1986-12-05 1988-06-15 Mect Corporation Inhaler
GB2248400A (en) * 1990-10-02 1992-04-08 Atomic Energy Authority Uk Powder inhaler
GB2253200A (en) * 1991-02-01 1992-09-02 Harris Pharma Ltd Inhalation apparatus and fracturable capsule for use therewith
AT396333B (en) * 1982-10-08 1993-08-25 Glaxo Group Ltd DEVICE FOR THE ADMINISTRATION OF MEDICINES TO PATIENTS, DEVICE WITH SEVERAL SUCH DEVICES AND CARRIERS WITH MEDICINE CONTAINERS HIEFUER
WO1994028958A1 (en) * 1993-06-03 1994-12-22 Boehringer Ingelheim Kg Capsule holder
US5379763A (en) * 1992-07-28 1995-01-10 Bespak Plc Dispensing apparatus for powdered medicaments
WO2000007572A2 (en) * 1998-08-05 2000-02-17 Boehringer Ingelheim Pharma Kg Two-piece capsule for receiving pharmaceutical preparations for powder inhalers
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
EP1238680A1 (en) * 2001-03-05 2002-09-11 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
WO2005046586A2 (en) 2003-11-04 2005-05-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005104745A2 (en) 2004-04-27 2005-11-10 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2006104889A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Novel compounds
US7135600B2 (en) 2001-02-14 2006-11-14 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
US7271197B2 (en) 2002-04-25 2007-09-18 Glaxo Group Limited Phenethanolamine derivatives
US7294650B2 (en) 2003-12-17 2007-11-13 Glaxo Group Limited Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders
US7361787B2 (en) 2001-09-14 2008-04-22 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7402598B2 (en) 2002-07-25 2008-07-22 Glaxo Group Limited Arylethanolamine β2-adrenoreceptor agonist compounds
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
US7442839B2 (en) 2002-10-28 2008-10-28 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
US7495010B2 (en) 2003-07-17 2009-02-24 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7507747B2 (en) 2003-10-17 2009-03-24 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP2039700A2 (en) 2001-04-30 2009-03-25 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
US7538127B2 (en) 2003-02-14 2009-05-26 Glaxo Group Limited Medicinal compounds
US7556035B2 (en) 2004-05-28 2009-07-07 Quadrant Technologies Limited Unit dose dry powder inhaler
US7576096B2 (en) 2003-10-14 2009-08-18 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7598267B2 (en) 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US7846973B2 (en) 2004-04-02 2010-12-07 Theravance, Inc. Chemical process and new crystalline form
WO2010147947A2 (en) 2009-06-16 2010-12-23 Schering Corporation NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
US7956065B2 (en) 2008-09-08 2011-06-07 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
EP2363121A1 (en) 2002-02-04 2011-09-07 Glaxo Group Limited Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor agonist for the treatment of inflammatory and allergic conditions
US8109267B2 (en) 2006-05-16 2012-02-07 Hovione International Ltd. Simple inhaler
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
WO2012028662A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2436686A1 (en) 2005-03-25 2012-04-04 Glaxo Group Limited Pyrimidopyridine compound used as a CSBP/RK/p38 modulator
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
WO2013045431A1 (en) 2011-09-27 2013-04-04 Glaxo Group Limited Sulfonamide compounds and their use in the modulation retinoid - related orphan receptor
WO2013160418A1 (en) 2012-04-27 2013-10-31 Glaxo Group Limited Novel compounds
WO2013160419A1 (en) 2012-04-27 2013-10-31 Glaxo Group Limited Novel compounds
US8662076B2 (en) 2005-01-11 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
US9365905B2 (en) 2005-02-10 2016-06-14 Dmv-Fonterra Excipients Technology Gmbh Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
WO2016203400A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2016203401A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2017029602A2 (en) 2015-08-16 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Compounds for use in antibacterial applications
WO2017060855A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
WO2017060854A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
WO2018055524A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055526A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018104766A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
WO2018109648A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
WO2018109649A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Ether linked triazoles as nrf2 regulators
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109643A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 acti
WO2018109647A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
WO2018200425A1 (en) 2017-04-24 2018-11-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
WO2019116230A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019115640A1 (en) 2017-12-15 2019-06-20 Glaxosmithkline Intellectual Property Development Limited 6-(morpholin-4-yl)-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine derivatives as m-tor inhibitors
WO2019141694A1 (en) 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiiibeta inhibitors
WO2019224667A1 (en) 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Indanes as nrf2 activators
WO2020023813A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
WO2020055858A1 (en) 2018-09-10 2020-03-19 Cocrystal Pharma, Inc. Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
WO2020081751A1 (en) 2018-10-17 2020-04-23 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
WO2020102270A1 (en) 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
WO2020112716A1 (en) 2018-11-26 2020-06-04 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
WO2020249652A1 (en) 2019-06-13 2020-12-17 Glaxosmithkline Intellectual Property Development Limited Pyridyl or pyrimidyl mtor kinase inhibitors
EP3782996A1 (en) 2015-06-15 2021-02-24 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
WO2021188620A1 (en) 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
WO2021206876A1 (en) 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
WO2023014758A1 (en) 2021-08-03 2023-02-09 Cocrystal Pharma, Inc. Inhibitors for coronaviruses

Cited By (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT396333B (en) * 1982-10-08 1993-08-25 Glaxo Group Ltd DEVICE FOR THE ADMINISTRATION OF MEDICINES TO PATIENTS, DEVICE WITH SEVERAL SUCH DEVICES AND CARRIERS WITH MEDICINE CONTAINERS HIEFUER
EP0271029A2 (en) * 1986-12-05 1988-06-15 Mect Corporation Inhaler
EP0271029A3 (en) * 1986-12-05 1989-05-31 Mect Corporation Inhaler
GB2248400A (en) * 1990-10-02 1992-04-08 Atomic Energy Authority Uk Powder inhaler
GB2248400B (en) * 1990-10-02 1994-05-04 Atomic Energy Authority Uk Powder inhaler
US5724959A (en) * 1990-10-02 1998-03-10 Aea Technology Plc Powder inhaler with specific orifice and baffle arrangement
GB2253200A (en) * 1991-02-01 1992-09-02 Harris Pharma Ltd Inhalation apparatus and fracturable capsule for use therewith
US5379763A (en) * 1992-07-28 1995-01-10 Bespak Plc Dispensing apparatus for powdered medicaments
WO1994028958A1 (en) * 1993-06-03 1994-12-22 Boehringer Ingelheim Kg Capsule holder
US5947118A (en) * 1993-06-03 1999-09-07 Boehringer Ingelheim Kg Capsule holder
WO2000007572A2 (en) * 1998-08-05 2000-02-17 Boehringer Ingelheim Pharma Kg Two-piece capsule for receiving pharmaceutical preparations for powder inhalers
WO2000007572A3 (en) * 1998-08-05 2000-05-11 Boehringer Ingelheim Pharma Two-piece capsule for receiving pharmaceutical preparations for powder inhalers
CZ301558B6 (en) * 1998-08-05 2010-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Capsule for pharmaceutical compositions for powder inhalers
US8298575B2 (en) 1998-08-05 2012-10-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Two-part capsule to accept pharmaceutical preparations for powder inhalers
WO2002012266A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
EP2348032A2 (en) 2000-08-05 2011-07-27 Glaxo Group Limited 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
EP2067784A2 (en) 2000-08-05 2009-06-10 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivates as anti-flammatory agents
EP1775305A2 (en) 2000-08-05 2007-04-18 Glaxo Group Limited 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
US7135600B2 (en) 2001-02-14 2006-11-14 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US7442719B2 (en) 2001-02-14 2008-10-28 Glaxo Group Limited Methods using phenethanolamine derivatives for treatment of respiratory diseases
US6679255B2 (en) 2001-03-01 2004-01-20 Ivo E. Pera Inhaling device for dispensing powdered medicaments contained in a capsule through the respiratory tract
EP1238680A1 (en) * 2001-03-05 2002-09-11 Ivo Pera Inhaling device for dispersing powdered medicaments contained in a capsule through the respiratory tract
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
EP2039700A2 (en) 2001-04-30 2009-03-25 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
US7361787B2 (en) 2001-09-14 2008-04-22 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US7776895B2 (en) 2001-09-14 2010-08-17 Glaxo Group Limited Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
EP2042168A1 (en) 2001-09-14 2009-04-01 Glaxo Group Limited Inhalation device comprising phenethanolamine derivatives for treatment of respiratory diseases
US7982067B2 (en) 2001-09-14 2011-07-19 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
USRE44874E1 (en) 2001-09-14 2014-04-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US7439393B2 (en) 2001-09-14 2008-10-21 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US8198483B2 (en) 2001-09-14 2012-06-12 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
EP2363121A1 (en) 2002-02-04 2011-09-07 Glaxo Group Limited Pharmaceutical formulation for administration by inhalation comprising an androstane derivative and a beta-2-adrenoreceptor agonist for the treatment of inflammatory and allergic conditions
US7271197B2 (en) 2002-04-25 2007-09-18 Glaxo Group Limited Phenethanolamine derivatives
US7402598B2 (en) 2002-07-25 2008-07-22 Glaxo Group Limited Arylethanolamine β2-adrenoreceptor agonist compounds
US7442839B2 (en) 2002-10-28 2008-10-28 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
US7538127B2 (en) 2003-02-14 2009-05-26 Glaxo Group Limited Medicinal compounds
US7495010B2 (en) 2003-07-17 2009-02-24 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7576096B2 (en) 2003-10-14 2009-08-18 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7579361B2 (en) 2003-10-14 2009-08-25 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7507747B2 (en) 2003-10-17 2009-03-24 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7906531B2 (en) 2003-11-04 2011-03-15 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7563803B2 (en) 2003-11-04 2009-07-21 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7439255B2 (en) 2003-11-04 2008-10-21 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2005046586A2 (en) 2003-11-04 2005-05-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
US7294650B2 (en) 2003-12-17 2007-11-13 Glaxo Group Limited Benzothiophen and thiochrone containing phenethanolamine derivatives for the treatment of respiratory disorders
US7384946B2 (en) 2004-03-17 2008-06-10 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7846973B2 (en) 2004-04-02 2010-12-07 Theravance, Inc. Chemical process and new crystalline form
US8183257B2 (en) 2004-04-27 2012-05-22 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP2570128A1 (en) 2004-04-27 2013-03-20 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US8575347B2 (en) 2004-04-27 2013-11-05 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US8853404B2 (en) 2004-04-27 2014-10-07 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
WO2005104745A2 (en) 2004-04-27 2005-11-10 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US8309572B2 (en) 2004-04-27 2012-11-13 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7488827B2 (en) 2004-04-27 2009-02-10 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US9144571B2 (en) 2004-04-27 2015-09-29 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US9045469B2 (en) 2004-04-27 2015-06-02 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7498440B2 (en) 2004-04-27 2009-03-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7598267B2 (en) 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7556035B2 (en) 2004-05-28 2009-07-07 Quadrant Technologies Limited Unit dose dry powder inhaler
US8662076B2 (en) 2005-01-11 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
EP3199164A1 (en) 2005-02-10 2017-08-02 Glaxo Group Limited Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
US9365905B2 (en) 2005-02-10 2016-06-14 Dmv-Fonterra Excipients Technology Gmbh Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
EP2447266A1 (en) 2005-03-25 2012-05-02 Glaxo Group Limited Pyrimidopyridine compound used as a CSBP/RK/p38 modulator
EP2436686A1 (en) 2005-03-25 2012-04-04 Glaxo Group Limited Pyrimidopyridine compound used as a CSBP/RK/p38 modulator
WO2006104889A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Novel compounds
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
US8109267B2 (en) 2006-05-16 2012-02-07 Hovione International Ltd. Simple inhaler
WO2008118724A1 (en) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides as ikk2 inhibitors
US7956065B2 (en) 2008-09-08 2011-06-07 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compounds
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
WO2010147947A2 (en) 2009-06-16 2010-12-23 Schering Corporation NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2012028662A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
WO2012028663A1 (en) 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP2954888A1 (en) 2010-08-31 2015-12-16 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
WO2013045431A1 (en) 2011-09-27 2013-04-04 Glaxo Group Limited Sulfonamide compounds and their use in the modulation retinoid - related orphan receptor
WO2013160419A1 (en) 2012-04-27 2013-10-31 Glaxo Group Limited Novel compounds
WO2013160418A1 (en) 2012-04-27 2013-10-31 Glaxo Group Limited Novel compounds
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
EP3766878A1 (en) 2015-06-15 2021-01-20 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
WO2016203400A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2016203401A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
EP3782996A1 (en) 2015-06-15 2021-02-24 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
WO2017029602A2 (en) 2015-08-16 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Compounds for use in antibacterial applications
WO2017060855A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
WO2017060854A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
WO2018055524A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055526A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018104766A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109647A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
WO2018109643A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 acti
WO2018109648A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
WO2018109646A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
WO2018109649A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Ether linked triazoles as nrf2 regulators
WO2018200425A1 (en) 2017-04-24 2018-11-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
US11014941B2 (en) 2017-04-24 2021-05-25 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
WO2019116230A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019116231A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019115640A1 (en) 2017-12-15 2019-06-20 Glaxosmithkline Intellectual Property Development Limited 6-(morpholin-4-yl)-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine derivatives as m-tor inhibitors
WO2019141694A1 (en) 2018-01-17 2019-07-25 Glaxosmithkline Intellectual Property Development Limited Pi4kiiibeta inhibitors
WO2019224667A1 (en) 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Indanes as nrf2 activators
WO2020023813A1 (en) 2018-07-27 2020-01-30 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
WO2020055858A1 (en) 2018-09-10 2020-03-19 Cocrystal Pharma, Inc. Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
WO2020081751A1 (en) 2018-10-17 2020-04-23 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
WO2020102270A1 (en) 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations of influenza therapeutics
WO2020112716A1 (en) 2018-11-26 2020-06-04 Cocrystal Pharma, Inc. Inhibitors of influenza virus replication
WO2020249652A1 (en) 2019-06-13 2020-12-17 Glaxosmithkline Intellectual Property Development Limited Pyridyl or pyrimidyl mtor kinase inhibitors
WO2021188620A1 (en) 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
WO2021206876A1 (en) 2020-04-10 2021-10-14 Cocrystal Pharma, Inc. Inhibitors of norovirus and coronavirus replication
WO2021216547A1 (en) 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Pulmonary administration of ace2 polypeptides
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
WO2023014758A1 (en) 2021-08-03 2023-02-09 Cocrystal Pharma, Inc. Inhibitors for coronaviruses

Also Published As

Publication number Publication date
CY1308A (en) 1985-12-06
GB2064336B (en) 1984-03-14

Similar Documents

Publication Publication Date Title
US4353365A (en) Device for dispensing medicaments
GB2064336A (en) Device for dispensing medicaments
US4206758A (en) Device for dispensing medicaments
US4210140A (en) Device for dispensing medicaments
CA1089735A (en) Device for dispensing medicaments
EP0804935B1 (en) Powder inhaler
KR100269060B1 (en) Pharmaceutical powder cartrige with integrated metering device inhaler for powdered medicaments
EP0129985B1 (en) Inhalation device
US5301666A (en) Powder inhaler
JPS6155978B2 (en)
JPH0579343B2 (en)
JPS5841067B2 (en) Fun matsuzaiyoukiyuuniyuki
CZ198493A3 (en) Inhalator for inhaling pulverized medicaments from pellets
GB2064334A (en) Inhalation valve for administering powdered medicaments
GB1591405A (en) Device for dispensing medicaments
CZ290494A3 (en) Inhalator
KR810002091B1 (en) Device for dispensing medicaments
KR810001833B1 (en) Device for dispensing medicaments
SI8412129A8 (en) Inhalator
HUT69894A (en) Enhaler
IT9020407A1 (en) SYSTEM FOR INHALATION ADMINISTRATION OF POWDER DRUGS PREPARED IN SPECIAL CONTAINERS

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20001204